ClinicaliQ Trial Snapshot
- Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer — Recruiting • Phase II • Oncology • NCT06954480.
- Treatment Being Tested: Datopotamab deruxtecan (Dato-DXd) monotherapy versus Dato-DXd combined with the immunotherapy agent durvalumab in patients with PD-L1-negative metastatic triple-negative breast cancer (TNBC).
- Patient Eligibility Overview: Adults with advanced or metastatic TNBC that is confirmed PD-L1-negative, representing a patient population traditionally considered less likely to benefit from immunotherapy alone.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant…
Eligibility Snapshot
- : 1. Willing and able to provide written informed consent. 2. Ability to comply with the protocol. 3. Female ≥ 18 years of age. 4. Triple-negative disease, defined as tumour cells being: * Negative for ER with
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.